AFP and hepatocellular carcinoma: Furthermore, the boundaries between diagnostic serum biomarkers and therapeutic targets are becoming increasingly blurred, and circulating proteins, such as AFP, GPC3, and SALL4, have become biomarker‐guided precision medicines for HCC [18].